Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of TAK-438 in Healthy Chinese Adults
NCT03085836Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vonoprazan in gastroesophageal reflux disease (GERD), gastric ulcer and duodenal ulcer (3 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 9, Time to Reach Maximum Plasma Concentration at Day 9 and 3 more. Started Apr 2017; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on NCT03085836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085836.